Evidence map›Paper›PMID 40490674›Full record

ArticleCell biochemistry and biophysics2025

Rational Design of Chlorinated Hydroxyxanthone as Anticancer Agent: Molecular Docking, Molecular Dynamic Simulation, ADMET, One-Pot Synthesis, and In Vitro Evaluation.

Yehezkiel Steven Kurniawan, Harizal, Nela Fatmasari, Ervan Yudha, Jumina, Harno Dwi Pranowo, Eti Nurwening Sholikhah

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yehezkiel Steven KurniawanDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia.
HarizalDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Nela FatmasariDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Ervan YudhaDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia.
JuminaDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia. jumina@ugm.ac.id.
Harno Dwi PranowoDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Eti Nurwening SholikhahDepartment of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Funding

Universitas Gadjah Mada 4161/UN1.P1/Dit-Lit/PT.01.01/2025
6 · The paper itself

Abstract

Nowadays, the discovery of active anticancer agents has become urgent research due to the high mortality of cancer patients. Herein, we designed some chlorinated hydroxyxanthones to examine the effect of the presence and position of the chloro group on the inhibitory activity of the PDGFR. The molecular docking reveals that 5-chloro-1-hydroxyxanthone (5Cl) exhibited the strongest binding energy (-7.95 kcal/mol) against PDGFR. The molecular dynamic simulation results demonstrated a high stability of the 5Cl-PDGFR complex as revealed by the average RMSD (0.37 ± 0.15 Å) and RMSF (0.83 ± 0.64 Å), and two maintained hydrogen bonds with Cys673 through hydroxyl and carbonyl groups with an average bond distance of 2.29 ± 0.54 and 2.49 ± 0.64 Å, respectively. Afterward, 5Cl and other chlorinated hydroxyxanthones were synthesized in a one-pot reaction with a 15.1-25.2% yield. From the in vitro experiment, 5Cl exhibited the lowest IC

Indexed as

Antineoplastic AgentsDrug DesignMolecular Docking SimulationMolecular Dynamics SimulationXanthonesAnimalsHalogenationHumansMCF-7 CellsAntineoplastic AgentsXanthonesAnticancerChlorinated hydroxyxanthoneMolecular dockingMolecular dynamic simulationPlatelet-derived growth factor receptor (PDGFR)Tyrosine kinase inhibitor

Identifiers

PMID40490674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.